☆ 4.6 Article

PROTAC-Induced Glycogen Synthase Kinase 3ß Degradation as a Potential Therapeutic Strategy for Alzheimer's Disease

ACS CHEMICAL NEUROSCIENCE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Chemistry, Medicinal

Impact of PROTAC Linker Plasticity on the Solution Conformations and Dissociation of the Ternary Complex

Dhanushka Weerakoon et al.

Summary: In this study, the conformational behavior of two PROTACs, MZ1 and dBET6, was investigated using molecular dynamics simulations. The simulations revealed different linker conformational behaviors and a tendency towards an intramolecular lipophilic interaction between the two warheads. The dissociation mechanism of the von Hippel-Lindau-MZ1-BRD4 complex was also studied and shown to follow a two-step pathway.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2022)

添加到收藏夹

Review Biotechnology & Applied Microbiology

PROTAC targeted protein degraders: the past is prologue

Miklos Bekes et al.

Summary: Targeted protein degradation (TPD) is a new therapeutic modality that can tackle disease-causing proteins which are difficult to target with conventional small molecules. PROTAC molecules, utilizing the ubiquitin-proteasome system to degrade target proteins, has achieved clinical proof-of-concept and attracted significant industry activity. Future directions include identifying target classes suitable for TPD, expanding the use of ubiquitin ligases for precision medicine, and extending the modality beyond oncology.

NATURE REVIEWS DRUG DISCOVERY (2022)

添加到收藏夹

Review Neurosciences

Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward

Sara Melisa Arciniegas Ruiz et al.

Summary: The protein kinase GSK-3 is a promising drug discovery target in treating multiple pathological conditions. Over the last decade, a range of GSK-3 inhibitors have been developed, with an increase in the indications tested. Clinical and pre-clinical studies have uncovered new mechanisms and insights into the contribution of GSK-3 to neurodegeneration and CNS-related disorders.

FRONTIERS IN MOLECULAR NEUROSCIENCE (2022)

添加到收藏夹

Article Chemistry, Medicinal

Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One

Alessandra Salerno et al.

Summary: PROTAC-mediated protein degradation has led to a rethink in drug discovery, with researchers proposing to enrich PROTACs with other therapeutic modalities to enhance efficacy, minimize side effects, and reach undruggable targets. The development of multifunctional PROTACs, such as multitarget PROTACs, light-controllable PROTACs, PROTAC conjugates, and macrocycle-and oligonucleotide-based PROTACs, represents a promising approach to further enhance PROTAC effectiveness. Further steps are needed to advance the clinical investigation and translation of multifunctional PROTACs.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Chemistry, Medicinal

Linker-Dependent Folding Rationalizes PROTAC Cell Permeability

Vasanthanathan Poongavanam et al.

Summary: The cell permeability of proteolysis-targeting chimeras (PROTACs) is found to be correlated with their folded conformations and solvent-accessible 3D polar surface area in an apolar environment. Molecular dynamics (MD) simulations can be used for the prospective ranking of cell permeability in cereblon PROTAC design.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Chemistry, Medicinal

PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases

Xueyang Jiang et al.

Summary: A series of heterobifunctional small molecule PROTACs based on CRBN were designed and synthesized to effectively degrade GSK-3β protein and protect against cell death, showing potential for further investigation in the biological function of GSK-3β protein and its association with diseases.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Medicinal

The tale of proteolysis targeting chimeras (PROTACs) for Leucine-Rich Repeat Kinase 2 (LRRK2)

Markella Konstantinidou et al.

Summary: The paper introduces rational design and synthetic methodologies for proteolysis-targeting chimeras (PROTACs) targeting the recently-emerged target leucine-rich repeat kinase 2 (LRRK2). Two potent brain-penetrating kinase inhibitors were selected and modified to assemble a cereblon-targeting PROTAC, showing strong kinase inhibition and cell penetration capability. However, data on target protein degradation remains inconclusive, and reasons for inefficient degradation are discussed further.

CHEMMEDCHEM (2021)

添加到收藏夹

Article Chemistry, Medicinal

Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer's Disease Multitarget Drug Discovery?

Angela De Simone et al.

Summary: Alzheimer's disease is a result of systemic breakdown of different physiological networks, and targeting multiple biochemical targets or pathways may be more efficient in tackling the disease. Recent studies have shown efforts in developing MTDLs targeting GSK-3β enzyme, which has connections with AD pathogenesis.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease

Lailiang Qu et al.

Summary: Designing and synthesizing a series of highly potent GSK3 degraders, PT-65 has shown great potential in selectively inducing GSK3 degradation and ameliorating learning and memory impairments in an in vivo model of AD.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Medicinal

Integrative Modeling of PROTAC-Mediated Ternary Complexes

Gaoqi Weng et al.

Summary: Proteolysis-targeting chimeras (PROTACs) represent an emerging drug discovery technology that selectively induce targeted protein degradation. PROTAC-Model, an integrative computational method, was developed to predict PROTAC-mediated ternary complex structures and showed better performance in rational design of PROTACs.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery

George M. Burslem et al.

CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Glycogen synthase kinase-3 signaling in Alzheimer's disease

Elisabetta Lauretti et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2020)

添加到收藏夹

Article Chemistry, Multidisciplinary

Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations

Jaebong Jang et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)

添加到收藏夹

Review Neurosciences

The Role of Copper in Tau-Related Pathology in Alzheimer's Disease

Klara Zubcic et al.

FRONTIERS IN MOLECULAR NEUROSCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Structural modeling of GSK3β implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs

Meenakshisundaram Balasubramaniam et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Review Chemistry, Medicinal

Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review

M. Xu et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease

Angela De Simone et al.

ACS MEDICINAL CHEMISTRY LETTERS (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeted protein degradation: elements of PROTAC design

Stacey-Lynn Paiva et al.

CURRENT OPINION IN CHEMICAL BIOLOGY (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Molecular mechanisms of cereblon-based drugs

Tomoko Asatsuma-Okumura et al.

PHARMACOLOGY & THERAPEUTICS (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

A MedChem toolbox for cereblon-directed PROTACs

Christian Steinebach et al.

MEDCHEMCOMM (2019)

添加到收藏夹

Article Chemistry, Medicinal

Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

Ian Churcher

JOURNAL OF MEDICINAL CHEMISTRY (2018)

添加到收藏夹

Article Chemistry, Medicinal

Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3 beta and Tau-Aggregation Inhibitors

Annachiara Gandini et al.

JOURNAL OF MEDICINAL CHEMISTRY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

George M. Burslem et al.

CELL CHEMICAL BIOLOGY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups

Shuai Gao et al.

BIOORGANIC & MEDICINAL CHEMISTRY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase

Georg Petzold et al.

NATURE (2016)

添加到收藏夹

Review Pharmacology & Pharmacy

Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases

Eleonore Beurel et al.

PHARMACOLOGY & THERAPEUTICS (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib

Juan Manuel Dominguez et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2012)

添加到收藏夹

Article Chemistry, Medicinal

Benzofuran-based hybrid compound's for the inhibition of cholinesterase activity, β amyloid aggregation, and Aβ neurotoxicity

Stefano Rizzo et al.

JOURNAL OF MEDICINAL CHEMISTRY (2008)

添加到收藏夹

Article Clinical Neurology

Increased level of active GSK-3β in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration

K. Leroy et al.

NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2007)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors

JA Bertrand et al.

JOURNAL OF MOLECULAR BIOLOGY (2003)

添加到收藏夹

Article Biochemistry & Molecular Biology

Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription

MP Coghlan et al.

CHEMISTRY & BIOLOGY (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.